-
Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab
Gelissen, L. M. Y., Hogenboom, L., Toorop, A. A., Strijbis, E. M. M., van Oosten, B. W., de Jong, B. A., Killestein, J. & van Kempen, Z. L. E., 15 Dec 2025, In: Journal of the Neurological Sciences. 479, 125652.Research output: Contribution to journal › Article › Academic › peer-review
-
Elevated Fab glycosylation of autoantibodies maintained during B cell depletion therapy
Valk, A. M., Koers, J., Derksen, N. I. L., Hogenboom, L., van Kempen, Z., Killestein, J., Rutgers, A., Heeringa, P., Horváth, B., Kuijpers, T. W., van Ham, S. M., Brinke, A. T., van der Woude, D., Toes, R. E. M., Bos, N. A., Rispens, T., Bos, A., Kummer, L. Y., Wieske, L. & Koning, M. & 5 others, , 1 Dec 2025, In: Scientific reports. 15, 1, 14770.Research output: Contribution to journal › Article › Academic › peer-review
-
A personalized approach for anti-CD20 therapies in multiple sclerosis
Hogenboom, L., van Kempen, Z. L. E., Kalincik, T., Bar-Or, A. & Killestein, J., 1 Nov 2024, In: Multiple sclerosis and related disorders. 91, 105851.Research output: Contribution to journal › Comment/Letter to the editor › Academic
- All publications
